Experience of a Single Academic Center Using IL-1 Inhibition for Rare Dermatologic Conditions.

Evidence-based literature regarding management of rare and severe dermatologic disease is limited. Canakinumab and anakinra, two therapeutics used for inhibiting IL-1 pathways, have seen increased utilization for treatment of refractory dermatoses. We sought to better characterize the breadth of dermatologic conditions for which these medications could be utilized.

Citation

Daniel Gutierrez, Erik Peterson, Katerina Svigos, Alisa Femia, Andrew Franks, Kristen Lo Sicco. Experience of a Single Academic Center Using IL-1 Inhibition for Rare Dermatologic Conditions. Journal of drugs in dermatology : JDD. 2022 Feb 01;21(2):206-208

Mesh Tags

Substances

PMID: 35133119

search → result